E López-Knowles, PM Wilkerson, R Ribas, H Anderson, A Mackay, Z Ghazoui, A Rani, P Osin, A Nerurkar, L Renshaw, A Larionov, WR Miller, JM Dixon, JS Reis-Filho, AK Dunbier, LA Martin, M Dowsett
Breast Cancer Res
Aromatase inhibitors (AIs) are a vital component of estrogen receptor positive (ER+) breast cancer treatment. De novo and acquired resistance, however, is common. The aims of this study were to relate patterns of copy number aberrations to molecular and proliferative response to AIs, to study differences in the patterns of copy number aberrations between breast cancer samples pre- and post-AI neoadjuvant therapy, and to identify putative biomarkers for resistance to neoadjuvant AI therapy using an integrative analysis approach.